NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey League™ (NHL) Hall-of-Famer, Henrik Lundqvist, to launch Life DisRPted, a national campaign focused on raising awareness of recurrent pericarditis, its impact on quality of life, and the critical importance of early diagnosis and treatment. Lundqvist was diagnosed with recurrent pericarditis in 2021, ultimately leading to his decision to retire from the NHL. “When I was first diagnosed with recurrent pericarditis, it felt like being hit by a train. The persistent pain of pericarditis flares ultimately kept me from returning to the NHL and the game I love. In addition to the physical toll, I felt I was missing out on life with my family and friends,” said Henrik Lundqvist, Hall of Fame former goaltender for the New York Rangers. “While this experience has deeply affected me, my family, and
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- New York Rangers Legend Henrik Lundqvist Signs On For ‘Life DisRPted' Campaign [Forbes]Forbes
- Hockey Hall of Famer spreading awareness on heart condition that forced him into early retirement [FOX News]FOX News
- US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren's Disease, According to Spherix Global Insights [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
KNSA
Earnings
- 7/23/24 - Beat
KNSA
Sec Filings
- 9/25/24 - Form 4
- 9/23/24 - Form 144
- 9/4/24 - Form 4
- KNSA's page on the SEC website